Menopause Associated Vasomotor Symptoms Epidemiology Forecast 2025-2034

The menopause associated vasomotor symptoms epidemiology forecast suggests that hot flashes and night sweats affect a significant portion of women worldwide, especially as the global population of aging women increases. Hot flashes are one of the most common menopausal vasomotor symptoms, impacting about 74% of perimenopausal women. Research shows that 65% of women have hot flashes for over 2 years, and 36% experience them for more than 5 years. Additionally, it is reported that about 3 in 4 women, or 75% of women, experience hot flashes during the years leading up to menopause (known as perimenopause), according to the Cleveland Clinic.

Menopause Associated Vasomotor Symptoms Epidemiology Forecast Report Coverage

The “Menopause Associated Vasomotor Symptoms Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of menopause associated vasomotor symptoms. It projects the future incidence and prevalence rates of menopause associated vasomotor symptoms cases across various populations. The study covers age and type as major determinants of the menopause associated vasomotor symptoms population. The report highlights patterns in the prevalence of menopause associated vasomotor symptoms over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on menopause associated vasomotor symptoms epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Menopause Associated Vasomotor Symptoms Understanding: Disease Overview

Menopause-associated vasomotor symptoms (VMS), primarily hot flashes and night sweats, are common symptoms that many women experience during the menopausal transition. These symptoms are caused by changes in hormone levels. Studies show that the drop in estrogen, which affects the ability of the body to regulate temperature, can account for menopause-associated vasomotor symptoms.

Several factors can affect the severity and duration of menopause-associated vasomotor symptoms. Age is the most important factor, as symptoms typically start during perimenopause. Lifestyle factors, such as obesity, smoking, and lack of exercise, are reported to worsen these symptoms.

Menopause Associated Vasomotor Symptoms Epidemiology Perspective

The menopause associated vasomotor symptoms epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for menopause associated vasomotor symptoms epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The menopause associated vasomotor symptoms detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to the global cross-sectional survey of women with vasomotor symptoms (2021), the prevalence of moderate-to-severe menopause associated vasomotor symptoms was 40% in Europe, 34% in the United States, and 16% in Japan. A significant number of women were hormone therapy-averse, with 56% in Europe, 54% in the United States, and 79% in Japan, while 12% (Europe), 9% (United States), and 8% (Japan) were hormone therapy-contraindicated.
• As per a 2023 European cross-sectional survey, the prevalence of moderate-to-severe menopause associated vasomotor symptoms varied from 31% in France to 52% in Italy. Despite being eligible for hormone therapy, the majority of women were either in the hormone therapy-cautious or hormone therapy-averse group.
• It is estimated that about 3 in 4 women, or 75% of women, experience hot flashes during the years leading up to menopause (known as perimenopause), as per the Cleveland Clinic.
• The prevalence of menopause associated vasomotor symptoms in North America ranges from 41% to 77%, and are reported to severely impact quality of life, work productivity, daily activities, and sleep.

Country-wise Menopause Associated Vasomotor Symptoms Epidemiology Segment

The menopause associated vasomotor symptoms epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of menopause associated vasomotor symptoms varies significantly between countries due to differences in dietary habits, lifestyle choices, ethnic backgrounds, and the availability and use of hormone replacement therapy (HRT) and other treatments. Various studies have shown that the prevalence of moderate to severe vasomotor symptoms postmenopause is reported as 32% to 46% in the United States, 31% to 52% in Europe, and 16% in Japan.

Menopause Associated Vasomotor Symptoms: Treatment Overview

Hormone replacement therapy (HRT) is one of the primary menopause-associated vasomotor symptoms therapeutics for managing hot flashes and night sweats. HRT, available in different forms, including pills, patches, and gels, replaces the estrogen that the body no longer produces during menopause. Hormone replacement therapy is often combined with progestin for women who still have their uterus.

Several non-hormonal medications like selective serotonin-norepinephrine reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and clonidine are also available for women who cannot or prefer not to take hormones.

Key Questions Answered

• What are the key findings of menopause associated vasomotor symptoms epidemiology in the 8 major markets?
• What will be the total number of patients with menopause associated vasomotor symptoms across the 8 major markets during the forecast period?
• What was the country-wise menopause associated vasomotor symptoms epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of menopause associated vasomotor symptoms patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of menopause associated vasomotor symptoms during the forecast period of 2025-2034?
• What are the currently available treatments in the menopause associated vasomotor symptoms market?
• What are the disease risks, signs, symptoms, and unmet needs of menopause associated vasomotor symptoms?

Scope of the Menopause Associated Vasomotor Symptoms Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of menopause associated vasomotor symptoms based on several factors.
• The Menopause Associated Vasomotor Symptoms Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The menopause associated vasomotor symptoms report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.